Medication burden in the first 5 years following diagnosis of type 2 diabetes: findings from the ADDITION-UK trial cohort by Black, James A et al.
Medication burden in the ﬁrst 5 years
following diagnosis of type 2 diabetes:
ﬁndings from the ADDITION-UK trial
cohort
James A Black,1 Rebecca K Simmons,1 Clare E Boothby,1 Melanie J Davies,2
David Webb,2 Kamlesh Khunti,2 Gráinne H Long,1 Simon J Griffin1
To cite: Black JA,
Simmons RK, Boothby CE, et
al. Medication burden in the
first 5 years following
diagnosis of type 2 diabetes:
findings from the ADDITION-
UK trial cohort. BMJ Open
Diabetes Research and Care
2015;3:e000075.
doi:10.1136/bmjdrc-2014-
000075
Received 18 December 2014
Revised 4 May 2015
Accepted 18 May 2015
1MRC Epidemiology Unit,
University of Cambridge,
Cambridge, UK
2Department of
Cardiovascular Sciences,
Leicester Royal Infirmary,
Leicester, UK
Correspondence to
Professor Simon J Griffin;
simon.griffin@mrc-epid.cam.
ac.uk
ABSTRACT
Introduction: Individuals with screen-detected
diabetes are likely to receive intensified
pharmacotherapy to improve glycaemic control and
general cardiometabolic health. Individuals are often
asymptomatic, and little is known about the degree to
which polypharmacy is present both before, and after
diagnosis. We aimed to describe and characterize the
pharmacotherapy burden of individuals with screen-
detected diabetes at diagnosis, 1 and 5 years post-
diagnosis.
Methods: The prescription histories of 1026
individuals with screen-detected diabetes enrolled in
the ADDITION-UK trial of the promotion of intensive
treatment were coded into general medication types at
diagnosis, 1 and 5 years post-diagnosis. The
association between change in the count of several
medication types and age, baseline 10-year UK
Prospective Diabetes Study (UKPDS) cardiovascular
disease (CVD risk), sex, intensive treatment group and
number of medications was explored.
Results: Just under half of individuals were on drugs
unrelated to cardioprotection before diagnosis (42%),
and this increased along with a rise in the number of
prescribed diabetes-related and cardioprotective drugs.
The medication profile over the first 5 years suggests
multimorbidity and polypharmacy is present in
individuals with screen-detected diabetes. Higher
modeled CVD risk at baseline was associated with a
greater increase in cardioprotective and diabetes-related
medication, but not an increase in other medications.
Conclusion: As recommended in national guidelines,
our results suggest that treatment of diabetes was
influenced by the underlying risk of CVD. While many
individuals did not start glucose lowering and
cardioprotective therapies in the first 5 years after
diagnosis, more information is required to understand
whether this represents unmet need, or patient-
centered care.
Trial registration number: CNT00237549.
INTRODUCTION
Medication burden is high among indivi-
duals with established type 2 diabetes.
Results from a systematic review indicate that
patients with diabetes take in the range of 4
to 10 medications a day.1 In an American
study of 875 individuals with diabetes, 50%
reported taking seven or more prescription
medications a day.2 Estimates from English
patients with diabetes suggest an average of
six medications a day.3 Individuals with dia-
betes are prescribed a number of cardiopro-
tective drugs, but there is also evidence to
suggest high levels of prescription of other
drug classes for example, treatment for neur-
opathy,4 depression,5 and gastric and rheum-
atological symptoms.6 In 2012–2013 in
England, 9.3% of the total cost of prescrip-
tions in the National Health Service (NHS)
was related to diabetes.7 As treatment regi-
mens become more complex, patients are
more likely to experience adverse side
effects8 and less likely to remain adherent to
all prescribed medications.9 10
Less is known about treatment burden
among individuals with screen-detected or
recently diagnosed diabetes. Given that
population screening for diabetes has been
recommended by several national organiza-
tions and the NHS currently includes assess-
ment of risk of diabetes in its Health Checks
program,11 more individuals will be found
earlier in the disease trajectory. Further,
there is growing evidence for the beneﬁt of
intensive treatment of risk factors early in the
course of the disease,12 13 which suggests that
screen-detected patients may be prescribed a
Key messages
▪ Screen-detected diabetes is usually asymptom-
atic, but individuals often have multimorbidity.
▪ Just under half of individuals with screen-
detected diabetes are on drugs not related to
cardiovascular disease at diagnosis.
▪ Many individuals did not start glucose lowering
medication in the 5 years after diagnosis.
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larger number of cardioprotective drugs earlier than
they might previously have been. Although there is some
evidence that improved medication adherence may
improve health-related quality of life in symptomatic
patients with diabetes,14 15 individuals earlier in the
disease trajectory are unlikely to have symptoms and
may be less likely to adhere to complex medication
regimes.16 17 There is currently little knowledge of medi-
cation burden in people with screen-detected diabetes,
many of whom will have few or no symptoms. Guidelines
promote a multifactorial approach to diabetes care from
diagnosis that includes pharmacotherapy for multiple
cardiovascular disease (CVD)-related conditions.18 19
Despite the increasing number of individuals with
screen-detected diabetes, many of whom have comorbid-
ities, there is an absence of knowledge about what the
pharmacotherapy burden is at diagnosis in this popula-
tion, and how it changes in the ﬁrst 5 years. It is import-
ant that this is described so that patients and
practitioners are informed about the likely course and
burden of treatment. We aimed to (1) describe medica-
tion burden at diagnosis, 1 and 5 years in individuals
with screen-detected diabetes and (2) examine if age,
sex, intensive treatment or modeled 10-year CVD risk
was associated with the number of drugs individuals
were prescribed at 5 years after diagnosis.
METHODS
The ADDITION study is a primary care-based screening
and intervention study for type 2 diabetes
(ClinicalTrials.gov, CNT00237549). It was carried out in
Denmark, the Netherlands and two UK centers
(Leicester and Cambridge). The study has been
described in detail elsewhere.13 20 21 In this paper we
describe data from the two UK centers. Brieﬂy, indivi-
duals aged 40–69 years in Leicester were invited to
attend an Oral Glucose Tolerance Test (OGTT).
Individuals in Cambridge aged 40–69 years with a high
risk of diabetes in Cambridge (Cambridge Risk Score22
≥0.17) were invited to a stepwise screening program
including a random capillary glucose test and glycated
hemoglobin, followed by a fasting capillary glucose test
and a conﬁrmatory OGTT. Individuals were diagnosed
using the WHO 1999 deﬁnition of diabetes.23 Exclusion
criteria included pregnancy, lactation, an illness with a
likely prognosis of less than 1 year or a psychiatric illness
likely to limit study involvement or invalidate informed
consent. Individuals found to have diabetes were treated
according to the group to which their practice was allo-
cated: routine care using national guidelines19 or the
promotion of intensive multifactorial treatment. In the
intensive treatment group, general practitioners (GPs)
were encouraged through guidelines, educational meet-
ings and audits with feedback to introduce a stepwise
target-led drug treatment regime to reduce hypergly-
cemia, hypertension and hyperlipidaemia20 21 similar to
the STENO-2 study.24 Trained staff-assessed patients’
health at baseline, 1 and 5 years and collected biochem-
ical and anthropometric data according to standard
operating procedures. Self-report questionnaires were
used to collect information on sociodemographic infor-
mation, lifestyle habits and medication use. The study
was approved by the relevant ethics committees13 20 21
and all participants provided written informed consent.
Assessment of medication
In Cambridge, participants were encouraged to bring
their repeat prescription summaries to each health
assessment and self-reported medication was collected
via a health economics questionnaire which asks for
information on all prescribed medication.25 In Leicester,
prescription information could also be sourced directly
from the records of a peripatetic clinic. Medication data
were coded using the Anatomical Therapeutic Chemical
Classiﬁcation System (ATC).26 ATC codes were used to
derive counts for each participant within the following
23 classes of medication: insulin, metformin, sulphony-
lurea, thiazolidinediones, other glucose lowering medi-
cation, ace-inhibitors, β-blockers, calcium channel
blockers, diuretics, other blood pressure lowering medi-
cations, lipid lowering, antithrombotic, gastrointestinal-
related, skin-related, hormone-replacement therapy or
urogenital, systemic steroids, thyroid-related, anti-
inﬂammatory, analgesic, antiepileptic, psychiatric,
respiratory and eye-related. Medication counts in this
analysis refer to the number of the 23 classes prescribed
(not overall pill count), while medication agent refers to
1 of the 23 explored classes of medication. For several
analyses, these 23 categories were also collapsed into
diabetes-related (insulin, metformin, sulphonylurea,
thiazolidinediones, other glucose-lowering medication),
cardioprotective (ace-inhibitors, β-blockers, calcium
channel blockers, diuretics, other hypertension-related
medications, lipid-lowering, antithrombotic) and other
(remaining 11 classes). Medication types that were not
within these categories, for example acute medications
like antibiotics, were not included in these analyses.
Statistical analysis
Baseline and 5-year descriptive characteristics of the
cohort were summarized using means, medians and pro-
portions. We described the medication proﬁle of the
ADDITION-UK cohort at diagnosis, 1 and 5 years follow-
ing diagnosis. Using complete case linear regression, we
explored the mutually adjusted associations between
age, baseline 10-year UK Prospective Diabetes Study
(UKPDS) CVD risk,27 sex, treatment group and baseline
number of medications on (1) change in total number
of medications, (2) change in cardioprotective medica-
tions and (3) change in other medications between diag-
nosis and 5 years. Owing to the distribution of change in
diabetes-related medication being left-censored at zero
an analogous Poisson regression model was used to
explore the association between baseline predictors and
change in diabetes-related medication over 5 years. SEs
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were used to adjust for clustering by GP practice in the
models. As current guidelines for the treatment of type
2 diabetes are very similar to the protocol used in the
intensive treatment arm of ADDITION-UK, and the
achieved difference in treatment was small, treatment
arms were pooled for the primary analysis.13 28 A sensi-
tivity analyze by randomization arm showed little differ-
ences relative to overall changes.
In order to characterize missing data, we used logistic
regression models to derive the odds of being included
in the complete-case analysis, individually adjusted for
age, sex, baseline UKPDS 10-year CVD risk, treatment
group and 2004 indices of multiple deprivation (IMD).
IMD scores were only available for the 867 individuals
(86% of the sample) from the Cambridge area, so the
association between missing data and socioeconomic
status is described using a smaller data set for this sensi-
tivity analysis.
The small differences in the outcome and treatment
between routine care and intensive treatment in
ADDITION-Europe has been linked to the continual
improvement of routine care, most likely accelerated
through the introduction of the Diabetes National
Service Framework in 2001,29 clinical guidelines for tar-
geting blood pressure and lipids in people with diabetes
in 2002,19 and the Quality and Outcomes Framework in
2004.13 29 Current guidelines for the treatment of type 2
diabetes are similar to the protocol used in the intensive
treatment arm of ADDITION-UK.13 28 As such, while a stat-
istically signiﬁcant difference in cardioprotective and
glucose-lowering drugs is present, absolute differences in
the prevalence of medications being reported are small,
which is why treatment arms were pooled in this analysis.
Statistical analyses were performed using R 3.0.2
(checkpoint 2014-09-18).
RESULTS
At diagnosis, the ADDITION-UK cohort had a mean age
of 61 years (SD 7), a median UKPDS 10-year CVD risk of
19% (IQR 13, 27) and 61% were male (tables 1 and 2).
Of the 1026 individuals in the ADDITION-UK cohort,
1024 (99.8%) had medication data at diagnosis, 1008
(99% of living) at 1 year, and 930 (96% of living) at
5 years. Ten people died before 1 year follow-up, and 59
before 5-year follow-up.
Total medication burden
At diagnosis, most individuals reported taking two medica-
tions (median 2; IQR 0, 4). This was most commonly a car-
dioprotective medication (median 1; IQR 0, 3), although
some individuals were on more than one non-
cardioprotective medication at diagnosis (ﬁgure 1). One
year after diagnosis a median of 3 medications (IQR 0,6)
were recorded. At 5 years, individuals were typically pre-
scribed six medications (median 6; IQR 5, 8), which
included one diabetes-related medication (median 1; IQR
0, 1), four cardioprotective medications (median 4; IQR 3,
5) and one other medication (median 1; IQR 0, 2).
Diabetes-related and cardioprotective medication
After diagnosis, both the variety and number of cardio-
protective and diabetes medications increased (ﬁgure 2).
At 1 year, 23% of individuals were prescribed any type of
diabetes medication, which increased to 62% at 5 years.
Between diagnosis, 1 and 5 years, the prescription of anti-
hypertensive (55% to 51% to 77%), lipid-lowering (24%
to 48% to 81%) and anti-thrombotic (20% to 36%
to 54%) medication increased. In this screen-detected
population, many individuals reported using no glucose
lowering medication at 1 and 5 years (78% and 38%,
respectively, ﬁgures 1 and 2).
Table 1 Baseline characteristics of the ADDITION-UK cohort, overall and by previous CVD status and CVD risk quartile
10-year UKPDS
CVD risk:
Lowest quartile
5,17
10-year UKPDS
CVD risk:
Highest quartile
3692 No CVD
Previous
CVD* Total
N† 244 244 858 106 1026
Mean age in years (SD) 55.6 (7.5) 64.2 (5.3) 60.3 (7.5) 63.1 (5.3) 60.6 (7.4)
Male % 40% 83% 60% 74% 61%
White % 80% 98% 93% 96% 91%
Median 10-year CVD risk (IQR) 14 (11, 15) 47 (40, 56) 24 (17, 33) 45 (35, 56) 25 (17, 36)
Mean BMI kg/m2 (SD) 32.8 (5.8) 33.0 (5.8) 33.3 (5.7) 32.9 (6.1) 30.8 (5.4)
Mean HbA1C % 6.6 (1.1) 8.3 (2.2) 7.4 (1.7) 7.1 (1.6) 7.3 (1.7)
Mean HbA1C mmol/mol 49 (12) 68 (24) 57 (19) 53 (17) 57 (18)
Mean systolic BP mm Hg (SD) 133 (16) 153 (23) 143 (19) 139 (22) 146 (17)
Mean total cholesterol mmol/L (SD) 5.2 (1.0) 5.5 (1.3) 5.5 (1.1) 4.6 (1.0) 5.6 (1.2)
Self-reported CVD* % 1% 30% 0% 100% 11%
Self-reported high-blood pressure % 60% 55% 57% 68% 59%
Self-reported high cholesterol % 27% 31% 23% 68% 28%
*Previous myocardial infarction or stroke.
†Number of participants recruited at diagnosis.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HbA1c, glycated hemoglobin; UKPDS, UK Prospective Diabetes
Study.
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Other medications
At diagnosis, 42% of individuals were prescribed other
types of medication, which increased to 62% at 5 years
after diabetes diagnosis (ﬁgure 2). The most common
was for gastrointestinal conditions (13% at diagnosis,
and 25% at 5 years). Many individuals also reported anti-
inﬂammatory (12% at diagnosis, and 12% at 5 years),
analgesic (12% at diagnosis, and 19% at 5 years) and
psychotherapy (11% at diagnosis, and 15% at 5 -
years)-related prescriptions.
Association between baseline characteristics and number
of prescribed drugs at 5 years
The baseline characteristics associated with an increase
in the total number of prescribed drugs between diagno-
sis and 5 years were a younger age (β −0.03, 95% CI
−0.05 to −0.01), a higher baseline modeled 10-year
UKPDS CVD risk score (β 0.04, 95% CI 0.04, 95% CI
0.02 to 0.05), randomisation to the intensive treatment
arm of the trial (β 0.44, 95% CI 0.01 to 0.78), and being
prescribed less medications at diagnosis (β −0.49, 95%
CI −0.56 to −0.42). Sex was not associated with change
in total number of medications. Similarly, the baseline
characteristics associated with an increase in cardiopro-
tective medication were a higher 10-year CVD risk (β
0.02, 95% CI 0.01 to 0.02), randomization to the inten-
sive treatment arm (β 0.39, 95% CI 0.09 to 0.69) and
being prescribed less medication at baseline (β −0.50,
95% CI −0.56 to −0.44). An increase in diabetes-related
medication was associated with female sex (Incidence
Rate Ratio, IRR 0.86, 95% CI 0.75 to 0.99), younger age
(years; IRR 0.96, 95% CI 0.95 to 0.97), having a higher
baseline 10-year CVD risk (IRR 1.02, 95% CI 1.01 to
1.02) and randomization to the intensive treatment arm
(IRR 1.15, 95% CI 0.01 to 1.30).
Compared to individuals with medication data at
5 years, those without medication data were more likely
to be female (OR 0.56; 95% CI 0.35 to 0.89), older
(1 year; OR 0.97; 0.94 to 0.999), to have had a previous
CVD event (OR 0.49; 95% CI 0.29 to 0.90) and to be in
the intensive arm of the trial (OR 2.04; 95% CI 1.32 to
3.20). There was no association between loss to follow-up
and ethnicity (White vs other; OR 0.77; 95% CI 0.31 to
1.60) or socioeconomic deprivation (1 point IMD 2004
change; OR 0.99; 95% CI 0.97 to 1.02).
DISCUSSION
In a population of individuals with screen-detected type
2 diabetes, we described the prevalence of diabetes-
related, cardioprotective and other medications at diag-
nosis, 1 and 5 years post-diagnosis. Many individuals
were on medications not related to cardioprotection
before diagnosis (42%), and this increased along with a
rise in the number of diabetes-related and cardioprotec-
tive drugs. At 5 years, individuals were typically pre-
scribed six medications, including one diabetes-related
medication, four cardioprotective medications, and one
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other medication. This suggests that there is a signiﬁcant
degree of multimorbidity and polypharmacy present in
individuals with screen-detected diabetes. Following
diagnosis, individuals were more likely to be prescribed
diabetes-related medication if they were younger, female,
had a high modeled CVD and if they were randomized
to the intensive treatment arm of the trial. Younger indi-
viduals being prescribed more total and diabetes medi-
cation in the 5 years after diagnosis is in line with
previous literature that identiﬁed those with early dia-
betes as having worse glycaemic control elevated and
CVD risk factors.30 In older individuals, the balance
between treatment beneﬁts and harm may also become
less clear, which could also lead to the identiﬁed associ-
ation. Higher modeled CVD risk at baseline was asso-
ciated with a greater increase in cardioprotective
medication, but not an increase in other medications.
As recommended in national guidelines, our results
suggest that the treatment of diabetes was inﬂuenced by
the underlying risk of CVD.
This is the ﬁrst description of total medication burden
in a large cohort of individuals with screen-detected dia-
betes over 5 years of follow-up. In a subset of the Dutch
Hoorn Study, among 195 individuals with screen-detected
diabetes, 45% were taking blood-pressure lowering medi-
cation and 20% were taking lipid-lowering medication at
diagnosis.31 In ADDITION-UK at diagnosis, 55% of indivi-
duals were taking blood pressure-lowering medication,
and 24% lipid-lowering medication, in agreement with
the results of the Hoorn screening subsample. In a
separate publication from the Hoorn study, 2 weeks after
diagnosis 24% of the screen-detected and 78% of the
clinically detected individuals were prescribed oral
glucose-lowering medication.32 The step-wise screening
program carried out in ADDITION-Cambridge used the
Cambridge Risk Score to identify those at the highest risk
of undiagnosed diabetes.22 This score includes blood
pressure medication as a variable, which may have led to
an overestimate in the number of individuals taking anti-
hypertensive medication in this sample. In 2005–2006, in
an American population with long-standing diabetes,
90% of the population were taking glucose-lowering med-
ications, 78% were taking antihypertensives and 26%
were on statins.33 This contrasts with ADDITION-UK,
where glucose-lowering medications were less common
(62%, at 5 years), and statins were more common (54%,
at 5 years). Statin use was the pharmacotherapy that dif-
fered by the greatest margin between arms of the
ADDITION-UK trial (47% for routine care vs 60% after
the promotion of intensive care, at 5 years). Our results
suggest that the promotion of statin use is the most
readily accepted treatment after diagnosis compared to
the introduction of glucose-lowering treatment. In
ADDITION-Europe, we have previously demonstrated
that individuals with the worst cardiometabolic health at
diagnosis were the most likely to be prescribed glucose,
blood pressure and lipid lowering medication, and also
were likely to achieve the greatest reductions in individual
CVD risk factors over the 5 years immediately after
diagnosis.34
Figure 1 Proportions of
self-reported medication use in
the ADDITION-UK cohort at
diagnosis, 1 and 5 years. COPD,
chronic obstructive pulmonary
disease; CVD, cardiovascular
disease; HRT, hormone
replacement therapy.
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Previous literature has noted that the prescription of
cardioprotective medication often lags behind glucose-
lowering medication, suggesting a disproportionate
emphasis on controlling glucose over CVD risk reduc-
tion.33 35 In both arms of ADDITION-UK, use of antihy-
pertensive and lipid-lowering medication was reported
by around four-ﬁfths of the participants (77% and 81%,
respectively), and glucose-lowering and aspirin use was
reported for three-ﬁfths of the population (62% and
54%, respectively). Our results suggest that the prescrip-
tion of cardioprotective medication did not lag behind
that of glucose-lowering. Conversely, 20% of individuals
were on metformin at 1 year, and 57% at 5 years, despite
metformin being recommended as a ﬁrst line glucose-
lowering medication, and immediate initiation being
recommended by National Institute for Health and Care
Excellence if overweight or non-responsive to lifestyle
interventions.19 Variation in treatment could be a posi-
tive indicator of patient-centered care or a deﬁcit
between patient need and prescribed medication. More
detailed knowledge on the circumstances around
treatment choices in screen-detected populations would
help inform whether the prescription of cardioprotec-
tive and glucose-lowering medication should be higher
in this population, or that the proportions prescribed
medications in this study represent adequate care in
relation to GP and patient needs and priorities. An
increase in diabetes medication from diagnosis to
5 years was associated with being female, younger,
having a GP who was in the trial arm promoted to treat
intensively and having a higher baseline risk of a CVD
event. In the Hoorn study, 2 weeks after screen-detected
diabetes diagnosis, 24% of the population were taking
glucose-lowering medication.32 While previous literature
suggests there is no association between the prescription
of diabetes-related medication and gender.36 37
Strengths and limitations
ADDITION-UK is a large cohort (n=1026) with consist-
ency in outcome measurement and little loss to
follow-up in individuals prescription histories (4% at
5 years). ADDITION-UK (91% white ethnicity) was less
Figure 2 Count of medication
types reported in the
ADDITION-UK cohort at
diagnosis, 1 and 5 years. CVD,
cardiovascular disease.
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diverse than the UKPDS (81% white ethnicity),38 which
may limit generalisability. However, ADDITION-UK
remains the only study able to characterize medication
changes after screen-detected diabetes diagnosis while
receiving contemporary diabetes care. This analysis uses
prescribed medications, which is likely to be an over
count of the redeemed and consumed prevalence.
Some medications may also be available without a pre-
scription. Accuracy of medication data was improved by
encouraging participants to bring repeat prescriptions to
the health assessment, the use of a health economics
questionnaire25 and cross-referencing GP records to
collect medication data. For the secondary analysis of
change in medications, our analysis assumes that a
change from zero to one medication is directly compar-
able to a change from four to ﬁve, or two to one.
Medication was coded into 23 classes, but anti-infectives,
antiparasitics and antineoplastic medications (as deﬁned
by the ATC) were not included as they were acute (eg,
infections) or rare (eg, cancer). As this study collected
snapshots of medication use at baseline, 1 and 5 years
after diagnosis, we are not able to give accurate preva-
lences for acutely prescribed medications. The number
of medical agents was chosen over the raw pill count as
some medications can be taken as ‘combination’ pills,
or can be split across multiple doses. This could unduly
increase the impact of some medications that are taken
multiple times a day on the ﬁnal medication count.
There is also likely to be less agreement between the
doctor prescribed treatments and daily pill count, com-
pared to reported types of medical agent, as pill count
includes both agent and information on frequency and
method of dose. Information on non-CVD-related
comorbidities that may inﬂuence medication was not
collected. This analysis remains primarily descriptive,
and does not directly assess the relationship between
changes in cardiometabolic health and pharmacother-
apy. This analysis is unable to describe the pharmaco-
therapy of individuals that died during follow-up, and it
is likely that if medication at the time of death was avail-
able, it would introduce greater heterogeneity to this
analysis. There was no association between loss to
follow-up and change in medication, although this ana-
lysis was limited to the subsample of Cambridge partici-
pants (86% of the sample) due to the IMD scores not
being available for all centers.
Individuals with screen-detected diabetes are often
taking multiple medications before diagnosis, despite
being identiﬁed early in the diabetes disease trajectory.
This includes both cardioprotective medications, and
other medications including; gastrointestinal, anti-
inﬂammatories, analgesics and psychiatric/neurological
medications. After diagnosis, GPs and patients appear to
adopt pharmacological strategies that target both CVD
risk reduction and glycemia, providing evidence against
concerns of over-prioritizing glycemic targets. The
increased prescription of cardioprotective medication
was associated with higher baseline CVD risk, indicating
an association between need and care. While this result
is promising, it remains unclear if the prescription rates
of glycemic and cardioprotective medication in this
population with elevated cardiovascular risk reﬂect
individualized treatment based on patient led priorities
or a deﬁcit in the application of pharmacological
intervention.
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